Your browser is no longer supported. Please, upgrade your browser.
Settings
GLYC GlycoMimetics, Inc. daily Stock Chart
GLYC [NASD]
GlycoMimetics, Inc.
Index- P/E- EPS (ttm)-1.15 Insider Own0.70% Shs Outstand41.85M Perf Week7.39%
Market Cap754.56M Forward P/E- EPS next Y-1.48 Insider Trans-0.68% Shs Float40.74M Perf Month7.51%
Income-33.30M PEG- EPS next Q-0.28 Inst Own78.40% Short Float14.58% Perf Quarter-8.24%
Sales- P/S- EPS this Y24.30% Inst Trans0.05% Short Ratio6.66 Perf Half Y59.42%
Book/sh3.51 P/B5.14 EPS next Y-46.50% ROA-33.00% Target Price28.25 Perf Year309.77%
Cash/sh2.96 P/C6.09 EPS next 5Y- ROE-35.40% 52W Range3.82 - 26.05 Perf YTD7.39%
Dividend- P/FCF- EPS past 5Y-18.80% ROI- 52W High-32.44% Beta3.39
Dividend %- Quick Ratio15.60 Sales past 5Y- Gross Margin- 52W Low360.73% ATR1.05
Employees40 Current Ratio15.60 Sales Q/Q- Oper. Margin- RSI (14)47.72 Volatility5.19% 6.62%
OptionableYes Debt/Eq0.00 EPS Q/Q24.80% Profit Margin- Rel Volume0.41 Prev Close18.03
ShortableYes LT Debt/Eq0.00 EarningsMar 06 BMO Payout- Avg Volume892.35K Price17.60
Recom1.60 SMA205.15% SMA50-10.49% SMA20015.03% Volume188,265 Change-2.38%
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Mar-29-18 08:20AM  New Research Coverage Highlights Healthcare Trust of America, Drive Shack, Chemed, AMERISAFE, Medical Properties Trust, and GlycoMimetics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-20-18 09:24PM  GlycoMimetics Announces Pricing of Public Offering of Common Stock Business Wire
Mar-19-18 04:01PM  GlycoMimetics Announces Proposed Public Offering of Common Stock Business Wire -5.73%
Mar-14-18 05:55PM  GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018 Business Wire
Mar-07-18 09:00AM  GlycoMimetics to Present at Four Investor Conferences This Month Business Wire
Mar-06-18 10:16PM  Edited Transcript of GLYC earnings conference call or presentation 6-Mar-18 1:30pm GMT Thomson Reuters StreetEvents -17.84%
02:48PM  Why GlycoMimetics Is Tumbling 19.2% Today Motley Fool
08:30AM  Todays Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel Corporation ACCESSWIRE
07:51AM  GlycoMimetics reports 4Q loss Associated Press
07:30AM  GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results Business Wire
06:00AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 04:01PM  GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML Business Wire -5.90%
01:39PM  When Can We Expect A Profit From GlycoMimetics Inc (NASDAQ:GLYC)? Simply Wall St.
08:35AM  Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? Zacks
Feb-27-18 09:00AM  GlycoMimetics to Report Fourth Quarter and Year-End 2017 Financial Results on March 6, 2018 Business Wire
Feb-08-18 09:00AM  GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy Business Wire -7.48%
Jan-26-18 07:45AM  New Research: Key Drivers of Growth for NanoString Technologies, Oaktree Capital Group, Midstates Petroleum, GlycoMimetics, State Street, and Retail Properties of America Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-15-18 06:11AM  What Is GlycoMimetics Incs (NASDAQ:GLYC) Financial Position? Simply Wall St.
Jan-14-18 09:00AM  5 Biotech Stocks That Could Be Bought Out in 2018 Motley Fool
Jan-02-18 06:29AM  Has GlycoMimetics Incs (NASDAQ:GLYC): Earnings Momentum Changed Lately? Simply Wall St.
Dec-17-17 09:00AM  Here's Why GlycoMimetics Could Become a Takeover Target Motley Fool
Dec-15-17 09:00AM  GlycoMimetics Added To NASDAQ Biotechnology Index Business Wire
Dec-14-17 01:44PM  These 4 stocks are powering higher MarketWatch
Dec-13-17 09:16AM  Company News For Dec 13, 2017 Zacks
Dec-12-17 04:59PM  Why This Biotech Stock Is Defying A Hematology-Related Pitfall Investor's Business Daily +14.87%
12:39PM  Here's Why GlycoMimetics Is Soaring 24.3% Higher Today Motley Fool
07:42AM  UPDATE: GlycoMimetics shares soar 30% after positive trial of leukemia treatment MarketWatch
07:00AM  GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 Business Wire
Dec-06-17 09:07AM  The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics Zacks
Dec-05-17 08:09AM  5 Top-Ranked Drug Stocks that are Broker Favorites Zacks
Nov-28-17 08:36AM  GlycoMimetics (GLYC) Jumps: Stock Rises 11.9% Zacks
Nov-27-17 12:20PM  What Is GlycoMimetics Incs (GLYC) Share Price Doing? Simply Wall St. +11.92%
Nov-09-17 09:15AM  GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Business Wire
Nov-08-17 02:36PM  Edited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents +8.60%
07:35AM  GlycoMimetics reports 3Q loss Associated Press
07:30AM  GlycoMimetics Reports Program Updates and Third Quarter 2017 Results Business Wire
06:50AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 08:36AM  Why Earnings Season Could Be Great for GlycoMimetics (GLYC) Zacks +7.95%
Nov-01-17 09:25AM  GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017 Business Wire
09:18AM  GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting Business Wire
Oct-17-17 10:12AM  GlycoMimetics, Inc. Value Analysis (NASDAQ:GLYC) : October 17, 2017 Capital Cube
Oct-16-17 08:34AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : October 16, 2017 Capital Cube
Sep-26-17 08:57AM  GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher Zacks -6.46%
Sep-11-17 10:39AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017 Capital Cube
Sep-05-17 09:00AM  GlycoMimetics to Present at Biocenturys Newsmakers in the Biotech Industry Conference Business Wire
08:47AM  Can GlycoMimetics (GLYC) Run Higher on Strong Earnings Estimate Revisions? Zacks
Aug-25-17 08:36AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 25, 2017 Capital Cube
Aug-08-17 08:22AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017 Capital Cube
Aug-04-17 03:17AM  GlycoMimetics reports 2Q loss Associated Press
Aug-03-17 09:15AM  GlycoMimetics Reports Program Updates and Second Quarter 2017 Results Business Wire
Aug-01-17 06:28PM  GlycoMimetics, Inc. Value Analysis (NASDAQ:GLYC) : August 1, 2017 Capital Cube
Jul-19-17 08:23AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017 Capital Cube
Jul-06-17 09:00AM  GlycoMimetics to Receive European Patent for GMI-1271 Business Wire
Jun-30-17 09:00AM  Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? Zacks
Jun-12-17 09:00AM  GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors Business Wire
Jun-07-17 08:00AM  Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics Accesswire -6.18%
Jun-05-17 04:00PM  GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference Business Wire -14.47%
12:47PM  Why GlycoMimetics Is Tumbling 13.4% Today Motley Fool
07:00AM  GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting Business Wire
May-31-17 09:00AM  GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271 Business Wire -5.44%
May-30-17 04:00PM  GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-25-17 04:01PM  Here's Why GlycoMimetics Rose as Much as 21% Today Motley Fool
09:25AM  GlycoMimetics GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia Business Wire
May-24-17 08:00AM  GlycoMimetics Announces Pricing of Public Offering of Common Stock Business Wire +5.66%
May-23-17 11:11AM  Shark Bites: There Wasn't Even a Dip to Buy TheStreet.com +20.35%
May-22-17 04:01PM  GlycoMimetics Announces Proposed Public Offering of Common Stock Business Wire -13.71%
08:00AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics Accesswire
May-19-17 01:55PM  ETFs with exposure to GlycoMimetics, Inc. : May 19, 2017 Capital Cube +19.59%
01:28PM  Why GlycoMimetics Is Ripping 19% Higher Today Motley Fool
08:35AM  GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7% Zacks
08:00AM  Today's Research Reports on Stocks to Watch: GlycoMimetics and Endologix Accesswire
May-18-17 03:15PM  Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today Zacks +98.70%
10:57AM  Don't Trust the Bounce Yet TheStreet.com
06:30AM  GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML Business Wire
May-17-17 04:10PM  GlycoMimetics GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia Business Wire
May-08-17 09:04AM  GlycoMimetics reports 1Q loss Associated Press
09:00AM  GlycoMimetics Reports Program Updates and First Quarter 2017 Results Business Wire
May-02-17 09:00AM  GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma Business Wire
Apr-20-17 10:44AM  GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting Business Wire
Apr-05-17 04:49PM  ETFs with exposure to GlycoMimetics, Inc. : April 5, 2017 Capital Cube
Mar-15-17 02:00PM  GlycoMimetics, Inc. :GLYC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
Mar-13-17 04:01PM  GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
09:30AM  GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors Business Wire
Mar-07-17 01:04PM  GLYCOMIMETICS INC Financials
09:00AM  GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 Business Wire
Mar-01-17 08:52PM  GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017 Business Wire
09:54AM  GlycoMimetics reports 4Q loss Associated Press
09:46AM  GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
09:33AM  GLYCOMIMETICS INC Files SEC form 10-K, Annual Report
09:30AM  GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results Business Wire
Feb-28-17 04:00PM  GlycoMimetics to Present at Cowen 37th Annual Health Care Conference Business Wire
Jan-12-17 02:45PM  Pharma company executives debate drug pricing increases Reuters
Dec-16-16 12:24AM  How Dawson Geophysical Company (DWSN) Stacks Up Against Its Peers Insider Monkey
Dec-05-16 10:01AM  GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML Business Wire
Nov-22-16 08:59AM  Novartis Buys Selexys on Favorable Phase II Data on SelG1
Nov-10-16 09:00AM  GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Business Wire
Nov-08-16 09:00AM  GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting Business Wire
Nov-04-16 09:46AM  GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
09:20AM  GlycoMimetics reports 3Q loss
09:15AM  GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development Business Wire
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thackray Helen M.SVP Clinical Development, CMODec 08Sale15.012,00030,020148,615Dec 12 04:14 PM
Thackray Helen M.SVP Clinical Development, CMOSep 18Sale13.002,00026,000150,615Sep 18 06:15 PM
Thackray Helen M.SVP Clinical Development, CMOMay 25Sale15.572,00031,140152,615May 30 04:07 PM
Thackray Helen M.SVP Clinical Development, CMOMay 19Sale12.142,00024,280154,615May 22 09:23 PM
Magnani John L.SVP of Research, CSOMay 10Option Exercise1.128,9289,99999,302May 11 04:00 PM